<DOC>
	<DOCNO>NCT00785538</DOCNO>
	<brief_summary>The purpose study determine IMC-A12 safe patient , also determine best dose IMC-A12 give patient .</brief_summary>
	<brief_title>A Study IMC-A12 Patients With Tumors Who No Longer Respond Treatment Who No Treatment Available</brief_title>
	<detailed_description>The purpose study establish safety profile maximum tolerate dose ( MTD ) anti-IGF-IR monoclonal antibody IMC-A12 administer weekly patient advance solid tumor longer respond standard therapy standard therapy available</detailed_description>
	<criteria>Histopathologicallydocumented , measurable , advanced primary recurrent solid tumor longer respond standard therapy standard therapy available . ECOG performance status score ≤ 2 study entry Able provide write inform consent Life expectancy &gt; 3 month Adequate hematologic function , define : ANC ≥ 1500mm3 , hemoglobin level ≥ 10 gm/dL , platelet count ≥ 100,000/mm3 Adequate hepatic function , define : total bilirubin level ≤ 1.5 x ULN , AST ALT level ≤ 2.5 x ULN ≤ 5 x ULN know liver metastasis Adequate renal function , define serum creatinine level ≤ 1.5 x ULN Ejection fraction within normal institutional limit Use effective contraception per institutional standard , procreative potential exists At least 28 day must elapse major surgery , prior chemotherapy , prior treatment investigational agent device , prior radiation therapy ( palliative radiation therapy allow ) , open biopsy , significant traumatic injury allow adequate recovery . Ongoing side effect due agent must ≤ grade 2 prior enter study . At least 6 week must elapse nitrosoureas , mitomycin C , monoclonal antibody ( target IGFR ) therapy allow adequate recovery . Ongoing side effect due agent must ≤ grade 2 prior enter study . Accessible treatment followup . Patients enrol trial must treat participate center . Any concurrent malignancy nonmelanomatous skin cancer carcinoma situ cervix . Patients previous malignancy without evidence disease ≥ 3 year allow enter trial . Uncontrolled intercurrent illness include , limited : ongoing active infection require parenteral antibiotic , symptomatic congestive heart failure , unstable angina pectoris , angioplasty , stenting myocardial infarction within 6 month , uncontrolled hypertension , clinically significant cardiac arrhythmia , psychiatric illness/social situation would compromise patient safety limit compliance study requirement , patient symptomatic brain metastasis Serious nonhealing active wound , ulcer bone fracture Know HIVpositive History hemorrhagic thrombotic disorder within 9 month Proteinuria ≥ 1+ routine urinalysis ( patient protein value ≤ 500mg confirm 24hour urine collection eligible ) Pregnant ( confirm serum beta human chorionic gonadotropin [ βHCG ] ) breast feed History prior treatment agent specifically target IGFRs Known diabetes Inability unwillingness interrupt steroidal hormonal therapy duration treatment IMCA12 Positive antiIMCA12 antibody response History allergic reaction monoclonal antibody therapeutic protein Employees investigator study center direct involvement study study direction investigator study center , well family member employee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Tumors</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>